688166.SHG BrightGene Bio Medical Technology C
- Market cap
- CNY 13.8B
- P/E
- 132.0x
- P/B
- 4.15x
- ROE
- 4.2%
- Dividend yield
- 0.85%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 688166.SHG undervalued?
Graham numberThe Graham number of BrightGene Bio Medical Technology C cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
BrightGene Bio Medical Technology C fundamental analysis
No fundamental analysis for BrightGene Bio Medical Technology C yet.
BrightGene Bio Medical Technology C stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About BrightGene Bio Medical Technology C
BrightGene Bio-Medical Technology Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical products in China and internationally. The company develops BGM0504 injection, which is in Phase III clinical trial for treatment of type 2 diabetes and weight loss; and BGM1812, a long-acting amylin analog in preclinical development. It also provides formulations; active pharmaceutical ingredients and intermediates; and ve…
Full company profileBrightGene Bio Medical Technology C financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
BrightGene Bio Medical Technology C annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 201M | 317M | 408M | 503M | 785M | 1.05B | 1.02B | 1.18B | 1.28B | 1.22B | 1.32B |
| Gross Profit | 116M | 187M | 238M | 322M | 431M | 592M | 641M | 658M | 738M | 622M | 735M |
| Operating Income | 18.7M | 56.5M | 86.8M | 126M | 208M | 274M | 265M | 254M | 251M | 110M | 186M |
| EBITDA | - | 69.5M | 97.6M | 146M | 224M | 309M | 316M | 311M | 321M | 236M | 196M |
| Net Income | 17.1M | 45.9M | 73.2M | 111M | 170M | 244M | 240M | 202M | 189M | 54.5M | 131M |
| EPS | - | 1.03 | 1.51 | 0.27 | 0.41 | 0.60 | 0.57 | 0.48 | 0.45 | 0.13 | 0.30 |
| Balance Sheet | |||||||||||
| Total Assets | 384M | 525M | 878M | 1.42B | 1.83B | 2.97B | 4.66B | 5.03B | 5.16B | 5.82B | 6.52B |
| Total Liabilities | 164M | 78.9M | 106M | 108M | 395M | 1.23B | 2.42B | 2.61B | 2.73B | 2.98B | 3.07B |
| Shareholders' Equity | 220M | 446M | 773M | 1.31B | 1.43B | 1.68B | 2.19B | 2.37B | 2.39B | 2.52B | 3.09B |
| Cash & Short-term Investments | 42.0M | 104M | 206M | 565M | 340M | 337M | 1.18B | 998M | 765M | 961M | 1.23B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 29.7M | 35.8M | 64.0M | 61.3M | 155M | 176M | 311M | 195M | 246M | 325M | - |
| Capital Expenditure | 36.6M | 83.7M | 112M | 89.5M | 355M | 910M | 727M | 389M | 257M | 453M | 251M |
| Free Cash Flow | - | -47.9M | -48.5M | -28.2M | -200M | -734M | -415M | -185M | -11.6M | -128M | 21.4M |
| Ratios | |||||||||||
| ROE | 7.7% | 10.3% | 9.5% | 8.5% | 11.9% | 14.5% | 10.9% | 8.5% | 7.9% | 2.2% | 4.2% |
| ROA | 4.4% | 8.7% | 8.3% | 7.8% | 9.3% | 8.2% | 5.1% | 4.0% | 3.7% | 0.9% | 2.0% |
| Net Profit Margin | 8.5% | 14.5% | 18.0% | 22.1% | 21.6% | 23.2% | 23.6% | 17.2% | 14.7% | 4.5% | 9.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
BrightGene Bio Medical Technology C dividends
- Dividend yield
- 0.85%
- Forward dividend
- 0.02 CNY
- Payout ratio
- 215.7%
- Ex-dividend date
- Jun 9, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 118M | 0.28 | 215.7% |
| 2024 | CNY 136M | 0.32 | 71.8% |
| 2023 | CNY 114M | 0.27 | 56.2% |
| 2022 | CNY 100M | 0.24 | 41.8% |
| 2021 | CNY 54.3M | 0.13 | 22.3% |
| 2020 | CNY 35.4M | 0.09 | 20.8% |
| 2019 | CNY 35.4M | 0.09 | 31.9% |
| 2018 | CNY 35.4M | 0.73 | 48.4% |
| 2017 | CNY 1.94M | 0.04 | 4.2% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns BrightGene Bio Medical Technology C
- Insiders 38.25%
- Institutions 12.43%
- Public & others 49.33%
- Shares outstanding 436M
- Free float 274M
BrightGene Bio Medical Technology C company profile
- Company name
- BrightGene Bio Medical Technology C
- Ticker
- 688166.SHG
- ISIN
- CNE100003PR1
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1,196
- Fiscal year end
- December
- Address
- Building C25-28, Suzhou, China, 215123
- Phone
- 86 512 6262 0988
- Website
- bright-gene.com
About BrightGene Bio Medical Technology C
BrightGene Bio-Medical Technology Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical products in China and internationally. The company develops BGM0504 injection, which is in Phase III clinical trial for treatment of type 2 diabetes and weight loss; and BGM1812, a long-acting amylin analog in preclinical development. It also provides formulations; active pharmaceutical ingredients and intermediates; and veterinary drugs for various therapeutic areas, including metabolism, respiratory, immunosuppression, antiviral, antifungal, antitumor, cerebrovascular, iron supplement, antibodies drug conjugate, anti-infection, imaging, intermediates, gynecology, cardiovascular, digestion, and others. In addition, the company is involved in technology research and development; import, export, wholesale, and retail of medicines; production and operation of medical devices; medical research and experimental development; and technical services. BrightGene Bio-Medical Technology Co., Ltd. was founded in 2001 and is based in Suzhou, China.
BrightGene Bio Medical Technology C management
5- Mr. Jiandong YuanChairman & GM · born 1970
- Mr. Kai LiEmployee Representative Director & Deputy GM · born 1976
- Ms. Nan DingBoard Secretary & Director · born 1991
- Mr. Chunlei ZhanChief Financial Officer · born 1987
- Fangsheng LiuAccounting Supervisor